Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""MYELOPROLIFERATIVE disorders"" wg kryterium: Temat


Tytuł :
Pathogenesis of cardiovascular events in BCR-ABL1-negative myeloproliferative neoplasms.
Autorzy :
Guy A; UMR1034, Inserm, Biology of Cardiovascular Diseases, University of Bordeaux, Pessac, France.; Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
Poisson J; Inserm, Centre de recherche sur l'inflammation, University of Paris, Paris, France.; Geriatrics Department, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
James C; UMR1034, Inserm, Biology of Cardiovascular Diseases, University of Bordeaux, Pessac, France. .; Laboratoire d'Hématologie, CHU de Bordeaux, Pessac, France. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Apr; Vol. 35 (4), pp. 935-955. Date of Electronic Publication: 2021 Mar 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Disease Susceptibility*
Cardiovascular Diseases/*etiology
Fusion Proteins, bcr-abl/*genetics
Myeloproliferative Disorders/*complications
Myeloproliferative Disorders/*genetics
Animals ; Biomarkers ; Blood Cells/immunology ; Blood Cells/metabolism ; Blood Coagulation ; Blood Coagulation Factors/metabolism ; Blood Vessels/metabolism ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/therapy ; Disease Management ; Disease Models, Animal ; Hemostasis ; Humans ; Mutation ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/epidemiology ; Risk Assessment ; Risk Factors ; Signal Transduction ; Thrombosis/blood ; Thrombosis/diagnosis ; Thrombosis/etiology
Czasopismo naukowe
Tytuł :
Complex landscape of alternative splicing in myeloid neoplasms.
Autorzy :
Hershberger CE; Cardiovascular and Metabolic Sciences Department, Cleveland Clinic Foundation, Cleveland, OH, USA.
Moyer DC; Cardiovascular and Metabolic Sciences Department, Cleveland Clinic Foundation, Cleveland, OH, USA.
Adema V; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, USA.
Kerr CM; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, USA.
Walter W; Munich Leukemia Laboratory, Munich, Germany.
Hutter S; Munich Leukemia Laboratory, Munich, Germany.
Meggendorfer M; Munich Leukemia Laboratory, Munich, Germany.
Baer C; Munich Leukemia Laboratory, Munich, Germany.
Kern W; Munich Leukemia Laboratory, Munich, Germany.
Nadarajah N; Munich Leukemia Laboratory, Munich, Germany.
Twardziok S; Munich Leukemia Laboratory, Munich, Germany.
Sekeres MA; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, USA.
Haferlach C; Munich Leukemia Laboratory, Munich, Germany.
Haferlach T; Munich Leukemia Laboratory, Munich, Germany.
Maciejewski JP; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, USA.
Padgett RA; Cardiovascular and Metabolic Sciences Department, Cleveland Clinic Foundation, Cleveland, OH, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Apr; Vol. 35 (4), pp. 1108-1120. Date of Electronic Publication: 2020 Aug 04.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Alternative Splicing*
Biomarkers, Tumor*
Gene Expression Regulation, Neoplastic*
Myeloproliferative Disorders/*genetics
Bone Marrow/pathology ; Bone Marrow Cells/metabolism ; Bone Marrow Cells/pathology ; Case-Control Studies ; Chromosome Deletion ; Cluster Analysis ; Disease Susceptibility ; Gene Expression Profiling ; Humans ; Loss of Function Mutation ; Mutation ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/therapy ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/therapy ; RNA Splicing Factors/genetics ; RNA Splicing Factors/metabolism ; Transcriptome
Czasopismo naukowe
Tytuł :
The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies.
Autorzy :
Gurnari C; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.; Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, 00133 Rome, Italy.
Pagliuca S; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Visconte V; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 19; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 19.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Biomarkers, Tumor*
Disease Susceptibility*
Energy Metabolism*
Mutation*
Myeloproliferative Disorders/*etiology
Myeloproliferative Disorders/*metabolism
Animals ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Gene Expression Profiling ; Gene Expression Regulation ; Humans ; Isocitrate Dehydrogenase/genetics ; Isocitrate Dehydrogenase/metabolism ; Metabolic Networks and Pathways ; Metabolomics ; Myeloproliferative Disorders/pathology ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/metabolism
Czasopismo naukowe
Tytuł :
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.
Autorzy :
Gangat N; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Tefferi A; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Mar 01; Vol. 96 (3), pp. 354-366. Date of Electronic Publication: 2020 Dec 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Myeloproliferative Disorders/*therapy
Pregnancy Complications/*therapy
Abortion, Habitual/etiology ; Abortion, Spontaneous/epidemiology ; Abortion, Spontaneous/prevention & control ; Anticoagulants/therapeutic use ; Aspirin/therapeutic use ; Combined Modality Therapy ; Female ; Heparin, Low-Molecular-Weight/therapeutic use ; Humans ; Infant, Low Birth Weight ; Infant, Newborn ; Interferon-alpha/therapeutic use ; Live Birth ; Multicenter Studies as Topic ; Mutation ; Myeloproliferative Disorders/drug therapy ; Myeloproliferative Disorders/genetics ; Phlebotomy ; Platelet Count ; Practice Guidelines as Topic ; Preconception Care ; Pregnancy ; Pregnancy Complications/drug therapy ; Pregnancy Complications/genetics ; Pregnancy Complications, Neoplastic/drug therapy ; Pregnancy Complications, Neoplastic/genetics ; Pregnancy Complications, Neoplastic/therapy ; Pregnancy Outcome ; Prenatal Care ; Puerperal Disorders/therapy ; Retrospective Studies ; Thrombophilia/drug therapy ; Thrombophilia/etiology ; Venous Thrombosis/etiology ; Venous Thrombosis/prevention & control
Czasopismo naukowe
Tytuł :
Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms.
Autorzy :
Chen NC; Department of Internal Medicine, The University of Texas School of Health Sciences at Houston, Houston, TX, USA.
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Mar; Vol. 62 (3), pp. 528-537. Date of Electronic Publication: 2020 Nov 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Hematologic Neoplasms*/drug therapy
Hematologic Neoplasms*/genetics
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Myeloproliferative Disorders*/drug therapy
Myeloproliferative Disorders*/genetics
Humans ; Protein Domains
Czasopismo naukowe
Tytuł :
Mutational analysis in different foci revealing the clonal evolution of blastic plasmacytoid dendritic cell neoplasm.
Autorzy :
Zhang X; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Zhu Y; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Yang M; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Wang L; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Yu W; Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.; Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Zhejiang, China.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Apr; Vol. 62 (4), pp. 988-991. Date of Electronic Publication: 2020 Nov 11.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematologic Neoplasms*/diagnosis
Hematologic Neoplasms*/genetics
Myeloproliferative Disorders*
Skin Neoplasms*
Clonal Evolution/genetics ; Dendritic Cells ; Humans
Raport
Tytuł :
The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens.
Autorzy :
Mundt KA; Cardno ChemRisk, Boston, MA, USA. .
Dell LD; Ramboll US Consulting Inc., Amherst, MA, USA.
Boffetta P; Stony Brook Cancer Center, Stony Brook, NY, USA.; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Beckett EM; Cardno ChemRisk, Boston, MA, USA.
Lynch HN; Cardno ChemRisk, Boston, MA, USA.
Desai VJ; Mount Sinai Hospital, New York, NY, USA.
Lin CK; Cardno ChemRisk, Boston, MA, USA.
Thompson WJ; Cardno ChemRisk, Boston, MA, USA.
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Mar 06; Vol. 21 (1), pp. 227. Date of Electronic Publication: 2021 Mar 06.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Epidemiologic Studies*
Carcinogens, Environmental/*adverse effects
Myelodysplastic Syndromes/*epidemiology
Myelodysplastic-Myeloproliferative Diseases/*epidemiology
Myeloproliferative Disorders/*epidemiology
Causality ; Humans ; Myelodysplastic Syndromes/chemically induced ; Myelodysplastic-Myeloproliferative Diseases/chemically induced ; Myeloproliferative Disorders/chemically induced
Czasopismo naukowe
Tytuł :
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study.
Autorzy :
Tondeur S; CHU Grenoble, Laboratoire de Génétique des hémopathies, Institut de Biologie et Pathologie, Grenoble, France.; CNRS UMR 5309, INSERM, U1209, Université Grenoble Alpes, Institute for Advanced Bioscience, Grenoble, France.
Paul F; CHU Montpellier, Service d'Hématologie clinique, Montpellier, France.
Riou J; Université d'Angers, INSERM 1066 MINT, Angers, France.
Mansier O; CHU de Bordeaux, Laboratoire d'Hématologie et Université de Bordeaux, Inserm U1034, Bordeaux, France.
Ranta D; CHU Nancy, Hématologie clinique, Nancy, France.
Le Clech L; CH Quimper, Hématologie Clinique, Quimper, France.
Lippert E; CHRU Brest, Laboratoire d'Hématologie, Brest, France.; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; Université Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.
Tavitian S; CHU Toulouse, Service d'Hématologie, Toulouse Oncopole, Toulouse, France.
Chaoui D; CH Argenteuil, Service d'Hématologie, Argenteuil, France.
Mercier M; CH Vannes, Hématologie clinique, Vannes, France.
De Renzis B; CHU Clermont-Ferrand, Hématologie clinique, Clermont-Ferrand, France.
Cottin L; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; CHU Angers, Laboratoire d'hématologie, Angers, France.; Université d'Angers, UFR Santé, Angers, France.; Université d'Angers, Inserm, CRCINA, F-49000, Angers, France.
Cassinat B; APHP, Hôpital Saint Louis, Laboratoire de Biologie Cellulaire, Paris, France.
Chrétien JM; CHU Angers, DRCI Cellule de Gestion des Données et Evaluation, Angers, France.
Ianotto JC; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; CHRU Brest, Service d'hématologie clinique, Brest, France.
Allangba O; CH Saint-Brieuc, Hématologie Clinique, Brest, France.
Marzac C; Gustave Roussy, Département de Biologie et Pathologie médicales, Brest, France.
Voillat L; Centre Hospitalier William Morey, Chalon-sur-Saône, France.
Boyer F; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; CHU Angers, Service des maladies du sang, Angers, France.
Orvain C; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; CHU Angers, Service des maladies du sang, Angers, France.
Hunault-Berger M; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; Université d'Angers, UFR Santé, Angers, France.; Université d'Angers, Inserm, CRCINA, F-49000, Angers, France.; CHU Angers, Service des maladies du sang, Angers, France.
Girodon F; CHU Dijon, Service d'Hématologie Biologique, Dijon, France.
Kiladjian JJ; APHP, Hôpital Saint Louis, INSERM UMRS 1131, Institut Universitaire d'Hématologie, Paris, France.
Ugo V; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France.; CHU Angers, Laboratoire d'hématologie, Angers, France.; Université d'Angers, UFR Santé, Angers, France.; Université d'Angers, Inserm, CRCINA, F-49000, Angers, France.
Luque Paz D; Fédération Hospitalo-Universitaire 'Grand Ouest Against Leukemia' (FHU GOAL), Brest, France. .; CHU Angers, Laboratoire d'hématologie, Angers, France. .; Université d'Angers, UFR Santé, Angers, France. .; Université d'Angers, Inserm, CRCINA, F-49000, Angers, France. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Mar; Vol. 35 (3), pp. 871-875. Date of Electronic Publication: 2020 Jul 21.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Exons*
Mutation*
Biomarkers, Tumor/*genetics
Janus Kinase 2/*genetics
Myeloproliferative Disorders/*pathology
Polycythemia Vera/*pathology
Adult ; Aged ; Cohort Studies ; Female ; Follow-Up Studies ; France ; Humans ; Male ; Middle Aged ; Myeloproliferative Disorders/genetics ; Polycythemia Vera/genetics ; Prognosis ; Survival Rate
Raport
Tytuł :
Highly increased risk of fracture in patients with myeloproliferative neoplasm.
Autorzy :
Johansson P; Section of Hematology and Coagulation, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Kristjansdottir HL; Section of Hematology and Coagulation, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Johansson H; Department of Public Health, McKillop Health Institute, Australian Catholic University, Melbourne, Australia.; Community of Medicine, University of Gothenburg Faculty of Health Sciences, Goteborg, Sweden.
Jakir A; Section of Hematology and Coagulation, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Mellström D; Center of Bone and Arthritis Research, University of Gothenburg Faculty of Health Sciences, Goteborg, Sweden.; Department of Geriatric Medicine, University of Gothenburg Faculty of Health Sciences, Goteborg, Sweden.
Lewerin C; Section of Hematology, Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Jan; Vol. 62 (1), pp. 211-217. Date of Electronic Publication: 2020 Sep 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Myeloproliferative Disorders*/complications
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/epidemiology
Polycythemia Vera*
Thrombocythemia, Essential*
Humans ; Sweden/epidemiology
Czasopismo naukowe
Tytuł :
Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
Autorzy :
Zhou S; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tremblay D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Hoffman R; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kremyanskaya M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Najfeld V; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Li L; Department of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Moshier E; Department of Population Health Science and Policy/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA, .
Pokaż więcej
Źródło :
Acta haematologica [Acta Haematol] 2021; Vol. 144 (1), pp. 48-57. Date of Electronic Publication: 2020 Mar 11.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antimetabolites, Antineoplastic/*therapeutic use
Decitabine/*therapeutic use
Myeloproliferative Disorders/*diagnosis
Myeloproliferative Disorders/*drug therapy
Aged ; Aged, 80 and over ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Biomarkers ; Chromosome Aberrations ; Combined Modality Therapy ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Female ; Gene Expression Profiling ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Mutation ; Myeloproliferative Disorders/etiology ; Myeloproliferative Disorders/mortality ; Neoplasm Staging ; Prognosis ; Retreatment ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Autorzy :
Mughal TI; Tufts University Medical Center, Boston, Massachusetts, USA.
Pemmaraju N; MD Anderson Cancer Center, Houston, Texas, USA.
Psaila B; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Radich J; Frederick Hutchinson Cancer Research Center, Seattle, Washington, USA.
Bose P; MD Anderson Cancer Center, Houston, Texas, USA.
Lion T; Childrens Cancer Research Institute, Vienna, Austria.
Kiladjian JJ; Hôpital Saint-Louis, Université de Paris, Paris, France.
Rampal R; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jain T; Sidney Kimmel Cancer Center, John Hopkins Hospital, Baltimore, Maryland, USA.
Verstovsek S; MD Anderson Cancer Center, Houston, Texas, USA.
Yacoub A; Division of Hematologic Malignancies, University of Kansas, Kansas City, Kansas, USA.
Cortes JE; Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.
Mesa R; Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, Texas, USA.
Saglio G; Orbassano University Hospital, Turin, Italy.
van Etten RA; University of California Irvine, Irvine, California, USA.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2020 Dec; Vol. 38 (5), pp. 654-664. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Disease Susceptibility*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*etiology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
Myeloproliferative Disorders/*etiology
Myeloproliferative Disorders/*therapy
Anemia/diagnosis ; Anemia/etiology ; Anemia/therapy ; Biomarkers ; Biomarkers, Tumor ; Combined Modality Therapy/adverse effects ; Combined Modality Therapy/methods ; Disease Management ; Drug Development ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis ; Molecular Diagnostic Techniques ; Molecular Targeted Therapy ; Myeloproliferative Disorders/complications ; Myeloproliferative Disorders/diagnosis ; Prognosis ; Single-Cell Analysis/methods ; Translational Medical Research ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.
Autorzy :
Nasillo V; Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Policlinico, 41124 Modena, Italy.
Riva G; Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Policlinico, 41124 Modena, Italy.
Paolini A; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Forghieri F; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Roncati L; Institute of Pathology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Lusenti B; Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Policlinico, 41124 Modena, Italy.
Maccaferri M; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Messerotti A; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Pioli V; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Gilioli A; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Bettelli F; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Giusti D; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Barozzi P; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Lagreca I; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Maffei R; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Marasca R; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Potenza L; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Comoli P; Pediatric Hematology/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy.
Manfredini R; Centre for Regenerative Medicine 'S. Ferrari', University of Modena and Reggio Emilia, 41125 Modena, Italy.
Maiorana A; Institute of Pathology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Tagliafico E; Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Policlinico, 41124 Modena, Italy.
Luppi M; Section of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, AOU Policlinico, 41124 Modena, Italy.
Trenti T; Department of Laboratory Medicine and Pathology, Diagnostic Hematology and Clinical Genomics, AUSL/AOU Policlinico, 41124 Modena, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Feb 14; Vol. 22 (4). Date of Electronic Publication: 2021 Feb 14.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Hematopoietic Stem Cells/*immunology
Immunotherapy/*methods
Inflammation/*immunology
Myeloproliferative Disorders/*therapy
T-Lymphocytes/*immunology
Tumor Microenvironment/*immunology
Calreticulin/genetics ; Calreticulin/immunology ; Calreticulin/metabolism ; Hematopoietic Stem Cells/metabolism ; Humans ; Inflammation/genetics ; Janus Kinase 2/genetics ; Janus Kinase 2/immunology ; Janus Kinase 2/metabolism ; Mutation/immunology ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/immunology ; Philadelphia Chromosome ; T-Lymphocytes/metabolism ; Tumor Microenvironment/genetics
Czasopismo naukowe
Tytuł :
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN.
Autorzy :
Stegelmann F; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany. .
Wille K; University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Busen H; Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.; Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.
Fuchs C; Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.; Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany.
Schauer S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Sadjadian P; University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Becker T; University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Kolatzki V; University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Döhner H; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Stadler R; University Clinic for Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Griesshammer M; University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany.
Pokaż więcej
Corporate Authors :
German Study Group-MPN
Źródło :
Leukemia [Leukemia] 2021 Feb; Vol. 35 (2), pp. 628-631. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*adverse effects
Fusion Proteins, bcr-abl/*genetics
Hydroxyurea/*adverse effects
Myeloproliferative Disorders/*drug therapy
Skin Diseases/*pathology
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Prognosis ; Prospective Studies ; Retrospective Studies ; Skin Diseases/chemically induced ; Survival Rate
Czasopismo naukowe
Tytuł :
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Autorzy :
Barbui T; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy. .
Vannucchi AM; Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Alvarez-Larran A; Hospital Clinic de Barcelona, Barcelona, Spain.
Iurlo A; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Masciulli A; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Carobbio A; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Ghirardi A; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Ferrari A; FROM Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy.
Rossi G; Spedali Civili, Brescia, Italy.
Elli E; Ospedale San Gerardo, ASST Monza, Monza, Italy.
Andrade-Campos MM; Hospital del Mar, Barcelona, Spain.
Kabat MG; Hospital Universitario la Paz, Madrid, Spain.
Kiladjian JJ; Hospital Saint-Louis, Paris, France.
Palandri F; Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italia.
Benevolo G; AOU Città della Salute e della Scienza di Torino, Torino, Italy.
Garcia-Gutierrez V; Hospital Ramon y Cajal, IRYCIS, Madrid, Spain.
Fox ML; Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, C/ Natzaret, 115-117, 08035, Barcelona, Spain.
Foncillas MA; Hospital Universitario Infanta Leonor, Madrid, Spain.
Morcillo CM; Hospital General Universitario de Albacete, Albacete, Spain.
Rumi E; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Osorio S; Hospital Gregorio Maranon, Madrid, Spain.
Papadopoulos P; Hospital Clinico San Carlos, Madrid, Spain.
Bonifacio M; Ospedale Policlinico 'G.B. Rossi', Borgo Roma, Verona, Italy.
Cervantes KSQ; Hospital Universitario de Mostoles, Madrid, Spain.
Serrano MS; ICO L'Hospitalet-Hospital Moises Broggi, Sant Joan Despì, Barcelona, Spain.
Carreno-Tarragona G; Hospital Universitario 12 de Octubre, Madrid, Spain.
Sobas MA; Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Lunghi F; IRCCS Ospedale San Raffaele, Milano, Italy.
Patriarca A; AOU Maggiore della Carità, Novara, Italy.
Elorza BN; Hospital Moncloa, Madrid, Spain.
Angona A; ICO Girona Hospital Josep Trueta, Girona, Spain.
Mazo EM; Hospital Universitario Principe de Asturias, Alcalà de Henares, Madrid, Spain.
Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Ruggeri M; Ospedale San Bortolo, Vicenza, Italy.
Cuevas B; Hospital Universitario de Burgos, Burgos, Spain.
Hernandez-Boluda JC; Hospital Clinico Universitario, INCLIVA, Valencia, Spain.
Abadia EL; Hospital General de Elche, Elche (Alicante), Spain.
Cirici BX; Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain.
Guglielmelli P; Center Research and Innovation of Myeloproliferative Neoplasms (CRIMM), Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.
Garrote M; Hospital Clinic de Barcelona, Barcelona, Spain.
Cattaneo D; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Daffini R; Spedali Civili, Brescia, Italy.
Cavalca F; Ospedale San Gerardo, ASST Monza, Monza, Italy.
Bellosillo B; Hospital del Mar, Barcelona, Spain.
Benajiba L; Hospital Saint-Louis, Paris, France.
Curto-Garcia N; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Bellini M; ASST Papa Giovanni XXIII, Bergamo, Italy.
Betti S; Fondazione Policlinico 'A. Gemelli' IRCCS, Rome, Italy.
De Stefano V; Fondazione Policlinico 'A. Gemelli' IRCCS, Rome, Italy.
Harrison C; Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Rambaldi A; ASST Papa Giovanni XXIII, Bergamo, Italy.; Università degli Studi di Milano, Milano, Italy.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Feb; Vol. 35 (2), pp. 485-493. Date of Electronic Publication: 2021 Jan 07.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
COVID-19/*mortality
Myeloproliferative Disorders/*mortality
Pyrazoles/*administration & dosage
SARS-CoV-2/*isolation & purification
Withholding Treatment/*statistics & numerical data
Aged ; COVID-19/complications ; COVID-19/transmission ; COVID-19/virology ; Europe/epidemiology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Myeloproliferative Disorders/drug therapy ; Myeloproliferative Disorders/epidemiology ; Myeloproliferative Disorders/virology ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Autorzy :
Yung Y; Division of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lee E; Division of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Chu HT; Division of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Yip PK; Division of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Gill H; Division of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Jan 11; Vol. 22 (2). Date of Electronic Publication: 2021 Jan 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Disease Susceptibility*
Hematopoietic Stem Cells/*metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*etiology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*therapy
Myeloproliferative Disorders/*etiology
Myeloproliferative Disorders/*therapy
Neoplastic Stem Cells/*metabolism
Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Autophagy ; Biomarkers, Tumor ; Cell Survival/drug effects ; Cell Transformation, Neoplastic/genetics ; Combined Modality Therapy ; Genetic Predisposition to Disease ; Hematopoietic Stem Cells/drug effects ; Hematopoietic Stem Cells/pathology ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology ; Molecular Targeted Therapy ; Myeloproliferative Disorders/pathology ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/pathology ; Philadelphia Chromosome ; Signal Transduction/drug effects ; Stem Cell Niche ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms.
Autorzy :
Garcia-Gisbert N; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Pompeu Fabra University, Barcelona, Spain.
Fernández-Ibarrondo L; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Pompeu Fabra University, Barcelona, Spain.
Fernández-Rodríguez C; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain.
Gibert J; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.
Andrade-Campos M; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain.
Arenillas L; Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain.
Camacho L; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain.
Angona A; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain.
Longarón R; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain.
Salar A; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain.
Calvo X; Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain.
Besses C; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Department of Haematology, Hospital del Mar-IMIM, Barcelona, Spain.
Bellosillo B; Group of Applied Clinical Research in Haematology, Cancer Research Program-IMIM (Hospital del Mar Medical Research Institute, Barcelona, Spain.; Pompeu Fabra University, Barcelona, Spain.; Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2021 Jan; Vol. 192 (2), pp. 300-309. Date of Electronic Publication: 2020 Sep 18.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cell-Free Nucleic Acids/*blood
Myeloproliferative Disorders/*blood
Adult ; Aged ; Aged, 80 and over ; Cell-Free Nucleic Acids/genetics ; DNA Mutational Analysis ; Female ; Humans ; Janus Kinase 2/genetics ; Male ; Middle Aged ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/genetics ; Receptors, Thrombopoietin/genetics
Czasopismo naukowe
Tytuł :
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Autorzy :
Palmieri R; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Othus M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Halpern AB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA.
Percival MM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA.
Godwin CD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA.
Becker PS; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA.
Walter RB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Medicine, Division of Hematology, University of Washington, Seattle, WA.; Department of Laboratory Medicine & Pathology & Department of Epidemiology, University of Washington, Seattle, WA.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Dec 10; Vol. 38 (35), pp. 4163-4174. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute/*drug therapy
Leukemia, Myeloid, Acute/*mortality
Myeloproliferative Disorders/*drug therapy
Myeloproliferative Disorders/*mortality
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cladribine/administration & dosage ; Consensus ; Cytarabine/administration & dosage ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Induction Chemotherapy ; Italy/epidemiology ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Mitoxantrone/administration & dosage ; Myeloproliferative Disorders/pathology ; Neoplasm Grading ; Predictive Value of Tests ; Severity of Illness Index ; Survival Rate ; Young Adult
Czasopismo naukowe
Tytuł :
CAR T cells for other pediatric non-B-cell hematologic malignancies.
Autorzy :
Lamble AJ; Division of Hematology-Oncology, Seattle Children's Hospital, Seattle, WA; and.; University of Washington School of Medicine, Seattle, WA.
Gardner R; Division of Hematology-Oncology, Seattle Children's Hospital, Seattle, WA; and.; University of Washington School of Medicine, Seattle, WA.
Pokaż więcej
Źródło :
Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2020 Dec 04; Vol. 2020 (1), pp. 494-500.
Typ publikacji :
Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy, Adoptive*
Hematologic Neoplasms/*therapy
Myeloproliferative Disorders/*therapy
Antigens, CD/metabolism ; Antigens, Neoplasm/metabolism ; Child, Preschool ; Hematologic Neoplasms/metabolism ; Hematologic Neoplasms/pathology ; Humans ; Male ; Myeloproliferative Disorders/metabolism ; Myeloproliferative Disorders/pathology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy
Czasopismo naukowe
Tytuł :
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease.
Autorzy :
Loscocco GG; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.
Mannelli F; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.
Mannelli L; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.; Doctorate School GEnoMEC, University of Siena, Siena, Italy.
Vergoni F; Department of Surgery and Translational Medicine, Division of Pathology, University of Florence, Florence, Italy.
Gesullo F; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.
Rotunno G; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.
Guglielmelli P; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.
Vannucchi AM; CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.; Department of Experimental and Clinical Medicine, University of Florence, DenoThe Excellence Center, Florence, Italy.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Dec; Vol. 95 (12), pp. 1622-1624. Date of Electronic Publication: 2020 Apr 17.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Leukemia, Mast-Cell*/blood
Leukemia, Mast-Cell*/genetics
Leukemia, Mast-Cell*/pathology
Leukemia, Mast-Cell*/therapy
Mutation*
Myeloproliferative Disorders*/blood
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/pathology
Myeloproliferative Disorders*/therapy
Neoplasm Proteins*/blood
Neoplasm Proteins*/genetics
Chromosomes, Human/*genetics
Aged ; Humans ; Male
Czasopismo naukowe
Tytuł :
Germline JAK2 V617F mutation as a susceptibility gene causing myeloproliferative neoplasm in first-degree relatives.
Autorzy :
Park HS; Laboratory Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.; Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Son BR; Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Shin KS; Laboratory Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Kim HK; Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.; Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Yang Y; Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.; Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Jeong Y; Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
Han HS; Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Lee KH; Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Kwon J; Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2020 Dec; Vol. 61 (13), pp. 3251-3254. Date of Electronic Publication: 2020 Aug 07.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Bone Marrow Neoplasms*
Myeloproliferative Disorders*/diagnosis
Myeloproliferative Disorders*/genetics
Germ Cells ; Humans ; Janus Kinase 2/genetics ; Mutation
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies